{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:36:24Z","timestamp":1795192584524,"version":"4.10.3"},"reference-count":45,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene therapy (GT) for adenosine deaminase\u2013deficient severe combined immune deficiency (ADA-SCID) can provide significant long-term benefit when patients are given nonmyeloablative conditioning and ADA enzyme-replacement therapy (ERT) is withheld before autologous transplantation of \u03b3-retroviral vector-transduced BM CD34+ cells. To determine the contributions of conditioning and discontinuation of ERT to the therapeutic effects, we analyzed these factors in Ada gene knockout mice (Ada\u2212\/\u2212). Mice were transplanted with ADA-deficient marrow transduced with an ADA-expressing \u03b3-retroviral vector without preconditioning or after 200 cGy or 900 cGy total-body irradiation and evaluated after 4 months. In all tissues analyzed, vector copy numbers (VCNs) were 100- to 1000-fold greater in mice receiving 900 cGy compared with 200 cGy (P &lt; .05). In mice receiving 200 cGy, VCN was similar whether ERT was stopped or given for 1 or 4 months after GT. In unconditioned mice, there was decreased survival with and without ERT, and VCN was very low to undetectable. When recipients were conditioned with 200 cGy and received transduced lineage-depleted marrow, only recipients receiving ERT (1 or 4 months) had detectable vector sequences in thymocytes. In conclusion, cytoreduction is important for the engraftment of gene-transduced HSC, and short-term ERT after GT did not diminish the capacity of gene-corrected cells to engraft and persist.<\/jats:p>","DOI":"10.1182\/blood-2012-02-408591","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T03:12:51Z","timestamp":1343272371000},"page":"3677-3687","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Gene therapy\/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction"],"prefix":"10.1182","volume":"120","author":[{"given":"Denise A.","family":"Carbonaro","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchao","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Research Immunology\/BMT, Children's Hospital Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jin","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Research Immunology\/BMT, Children's Hospital Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Rozengurt","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, UCLA, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gjertson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, UCLA, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Texas Medical School at Houston, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Blackburn","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Texas Medical School at Houston, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Kohn","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111809225706000_B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0952-7915(03)00104-3","article-title":"Genotype is an important determinant of phenotype in adenosine deaminase deficiency.","volume":"15","author":"Hershfield","year":"2003","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2019111809225706000_B2","first-page":"491","article-title":"Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase.","volume":"70","author":"Morgan","year":"1987","journal-title":"Clin Exp Immunol"},{"issue":"17","key":"2019111809225706000_B3","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","article-title":"How I treat ADA deficiency.","volume":"114","author":"Gaspar","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111809225706000_B4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","article-title":"Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).","volume":"117","author":"Chan","year":"2005","journal-title":"Clin Immunol"},{"issue":"11","key":"2019111809225706000_B5","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1002\/eji.200526248","article-title":"Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients.","volume":"35","author":"Malacarne","year":"2005","journal-title":"Eur J Immunol"},{"issue":"4673","key":"2019111809225706000_B6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.6093246","article-title":"Prospects for human gene therapy.","volume":"226","author":"Anderson","year":"1984","journal-title":"Science"},{"issue":"10","key":"2019111809225706000_B7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jmg.40.10.721","article-title":"In vivo reversion to normal of inherited mutations in humans.","volume":"40","author":"Hirschhorn","year":"2003","journal-title":"J Med Genet"},{"issue":"9","key":"2019111809225706000_B8","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood.V97.9.2896","article-title":"T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation.","volume":"97","author":"Ariga","year":"2001","journal-title":"Blood"},{"issue":"5235","key":"2019111809225706000_B9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years.","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"5235","key":"2019111809225706000_B10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA immunodeficient patients.","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"issue":"2","key":"2019111809225706000_B11","first-page":"179","article-title":"Bone marrow gene transfer in three patients with adenosine deaminase deficiency.","volume":"3","author":"Hoogerbrugge","year":"1996","journal-title":"Gene Ther"},{"issue":"10","key":"2019111809225706000_B12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nm1095-1017","article-title":"Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency.","volume":"1","author":"Kohn","year":"1995","journal-title":"Nat Med"},{"issue":"7","key":"2019111809225706000_B13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nm0798-775","article-title":"T lymphocytes with a normal Ada gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.","volume":"4","author":"Kohn","year":"1998","journal-title":"Nat Med"},{"issue":"5","key":"2019111809225706000_B14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.","volume":"8","author":"Aiuti","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"2019111809225706000_B15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm844","article-title":"Clonality analysis after retroviral-mediated gene transfer to cord blood CD34+ cells of an ADA-deficient SCID infant.","volume":"9","author":"Schmidt","year":"2003","journal-title":"Nat Med"},{"issue":"7","key":"2019111809225706000_B16","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2019111809225706000_B17","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2011-01-329359","article-title":"Comparative results of gene therapy for adenosine deaminase deficiency with or without PEG-ADA withdrawal and myelosuppressive chemotherapy.","volume":"118","author":"Sokolic","year":"2011","journal-title":"Blood"},{"issue":"5577","key":"2019111809225706000_B18","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"issue":"5","key":"2019111809225706000_B19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency.","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111809225706000_B20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol Ther"},{"issue":"12","key":"2019111809225706000_B21","first-page":"S296","article-title":"Update on a clinical gene therapy trial for adenosine deaminase deficient severe combined immune deficiency (ADA-SCID).","volume":"18","author":"Shaw","year":"2010","journal-title":"Mol Ther"},{"issue":"97","key":"2019111809225706000_B22","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"issue":"9","key":"2019111809225706000_B23","first-page":"980","article-title":"Improved retroviral vectors for gene transfer and expression.","volume":"7","author":"Miller","year":"1989","journal-title":"Biotechniques"},{"issue":"2","key":"2019111809225706000_B24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/JVI.69.2.748-755.1995","article-title":"Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells.","volume":"6","author":"Challita","year":"1995","journal-title":"J Virol"},{"issue":"17","key":"2019111809225706000_B25","doi-asserted-by":"crossref","first-page":"9439","DOI":"10.1128\/JVI.77.17.9439-9450.2003","article-title":"The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells.","volume":"77","author":"Haas","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"2019111809225706000_B26","first-page":"37","article-title":"Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells.","volume":"3","author":"Krall","year":"1996","journal-title":"Gene Ther"},{"issue":"4","key":"2019111809225706000_B27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1128\/JVI.62.4.1120-1124.1988","article-title":"A safe packaging line for gene transfer: separating viral genes on 2 different plasmids.","volume":"62","author":"Markowitz","year":"1988","journal-title":"J Virol"},{"issue":"9","key":"2019111809225706000_B28","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1074\/jbc.273.9.5093","article-title":"Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency.","volume":"273","author":"Blackburn","year":"1998","journal-title":"J Biol Chem"},{"issue":"41","key":"2019111809225706000_B29","doi-asserted-by":"crossref","first-page":"32114","DOI":"10.1074\/jbc.M005153200","article-title":"The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice.","volume":"275","author":"Blackburn","year":"2000","journal-title":"J Biol Chem"},{"issue":"12","key":"2019111809225706000_B30","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1182\/blood-2007-08-103663","article-title":"Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.","volume":"111","author":"Carbonaro","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111809225706000_B31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1165\/rcmb.2006-0276OC","article-title":"Development of lentiviral vectors with regulated respiratory epithelial expression in vivo.","volume":"37","author":"Hendrickson","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"2019111809225706000_B32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ymthe.2006.02.013","article-title":"In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knock-out mice: a novel form of enzyme replacement therapy for ADA-deficiency.","volume":"13","author":"Carbonaro","year":"2006","journal-title":"Mol Ther"},{"issue":"9","key":"2019111809225706000_B33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/jlts.2002.34891","article-title":"Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences.","volume":"8","author":"Wang","year":"2002","journal-title":"Liver Transpl"},{"issue":"1","key":"2019111809225706000_B34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/tera.1420450109","article-title":"Effects of R-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse.","volume":"45","author":"Knudsen","year":"1992","journal-title":"Teratology"},{"issue":"1","key":"2019111809225706000_B35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1214\/aoms\/1177707036","article-title":"Variances of variance components: II. Unbalanced single classifications.","volume":"28","author":"Tukey","year":"1957","journal-title":"Ann Mathematical Stat"},{"issue":"1","key":"2019111809225706000_B36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis.","volume":"47","author":"Kruskal","year":"1952","journal-title":"J Am Stat Assoc"},{"key":"2019111809225706000_B37","volume-title":"SAS\/STAT 9.2 User's Guide","author":"SAS Institute","year":"2008"},{"issue":"12","key":"2019111809225706000_B38","first-page":"S678","article-title":"Update of Stem Cell Gene Therapy Clinical Trial for ADA-deficiency in Japan.","volume":"18","author":"Otsu","year":"2010","journal-title":"Mol Ther"},{"issue":"12","key":"2019111809225706000_B39","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/gt.2009.96","article-title":"Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.","volume":"16","author":"Sadat","year":"2009","journal-title":"Gene Ther"},{"issue":"12","key":"2019111809225706000_B40","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1182\/blood.V99.12.4592","article-title":"Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation.","volume":"99","author":"Min","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111809225706000_B41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V99.3.1005","article-title":"Adenosine deaminase deficiency with mosaicism for a \u201csecond-site suppressor\u201d of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy.","volume":"99","author":"Arredondo-Vega","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111809225706000_B42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/mthe.2002.0535","article-title":"Adenosine deaminase gene therapy protocol revisited.","volume":"5","author":"Kohn","year":"2002","journal-title":"Mol Ther"},{"issue":"9","key":"2019111809225706000_B43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1172\/JCI9944","article-title":"Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures.","volume":"106","author":"Thompson","year":"2000","journal-title":"J Clin Invest"},{"issue":"15","key":"2019111809225706000_B44","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/blood-2009-03-209221","article-title":"ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANK\/OPG imbalance and osteoblast insufficiency.","volume":"114","author":"Sauer","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111809225706000_B45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10875-012-9658-3","article-title":"Non-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency.","volume":"32","author":"Booth","year":"2012","journal-title":"J Clin Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/18\/3677\/1359299\/zh804412003677.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/18\/3677\/1359299\/zh804412003677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T12:50:27Z","timestamp":1594471827000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/18\/3677\/30690\/Gene-therapybone-marrow-transplantation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,1]]},"references-count":45,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-02-408591","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,1]]}}}